Generic BETAMETHASONE DIPROPIONATE INN equivalents, drug patent expiration information and freedom to operate

Sponsor	Phase
MC2 Therapeutics	PHASE3
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	PHASE3
Jinnah Postgraduate Medical Centre	PHASE1

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SERNIVO	Topical Spray	betamethasone dipropionate	0.05%	208079	1	2018-02-15

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	OINTMENT, AUGMENTED;TOPICAL	209106-001	Dec 18, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Schering	DIPROSONE	betamethasone dipropionate	DISC;TOPICAL	017829-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Lifesciences	BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	OINTMENT;TOPICAL	214048-001	Jul 14, 2020	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	DIPROLENE	betamethasone dipropionate	CREAM, AUGMENTED;TOPICAL	019408-001	Jan 31, 1986	4,482,539	⤷ Start Trial
Organon	DIPROLENE	betamethasone dipropionate	OINTMENT, AUGMENTED;TOPICAL	018741-001	Jul 27, 1983	4,070,462	⤷ Start Trial
Schering	DIPROLENE	betamethasone dipropionate	CREAM, AUGMENTED;TOPICAL	019408-001	Jan 31, 1986	4,489,070	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Japan	5833007		⤷ Start Trial
Denmark	2473161		⤷ Start Trial
World Intellectual Property Organization (WIPO)	2011026076		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Last updated: January 17, 2026

Executive Summary

Betamethasone dipropionate, a potent synthetic corticosteroid, is widely used in dermatology for conditions like psoriasis, eczema, and dermatitis. Its market is shaped by clinical efficacy, regulatory approval, manufacturing capabilities, and evolving dermatological treatment protocols. The compound’s high potency, combined with increasing dermatological disorder prevalence globally, underpins a favorable market outlook. However, generic competition and regulatory shifts present challenges, influencing pricing and revenue streams. This comprehensive analysis explores market drivers, competitive landscape, regulatory environment, and financial forecasts, providing critical insights for stakeholders.

1. Overview of Betamethasone Dipropionate

Chemical Profile and Therapeutic Use

Chemical Name: 9-fluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylate 17-propionate 21-acetate.
Pharmacology: As a topical corticosteroid, it governs anti-inflammatory, immunosuppressive, and antipruritic actions.
Formulations: Creams, ointments, lotions, gels.
Indications: Psoriasis, eczema, dermatitis, allergic reactions.

Market Specifics

Current Annual Market Size (Global): Estimated around $2.8 billion (2022).
Major Regions:
- North America (~40%)
- Europe (~30%)
- Asia-Pacific (~20%)
- Rest of World (~10%)

Manufacturers

Branded products primarily by brands like Diprolone, Betaderm.
Major generics manufactured by industry giants: Mylan, Teva, Sandoz, etc.

2. Market Drivers

Prevalence of Dermatological Conditions

Condition	Global Prevalence (millions)	Trends	Impact
Psoriasis	~125	Rising, driven by aging population	Increased demand for potent corticosteroids like betamethasone dipropionate.
Eczema	~240	Increasing in developed nations	Growing prescription volume, especially in children and adults.
Contact dermatitis	~150	Persistent, expanding awareness	Sustains long-term dermatology treatments.

Regulatory Approvals and Guidelines

Recognized by FDA, EMA, and WHO as first-line therapy.
Guidelines recommend corticosteroids for moderate-to-severe cases, boosting prescription rates.

Innovation and Formulation Advances

Development of low-potency formulations for sensitive skin.
Combination products (e.g., corticosteroid + antibiotic) expand market utility.

3. Market Challenges and Restraints

Generic Competition and Pricing Pressure

Significant generic availability erodes margins over patent expiry periods.
Average price decline of 5-10% annually post-patent expiry.

Regulatory and Safety Concerns

Long-term steroid use linked to skin atrophy and systemic absorption issues.
Regulatory bodies impose warnings, potentially restricting usage or reimbursement.

Market Saturation and Regional Variability

Mature markets nearing saturation.
Underpenetrated regions face access barriers due to cost or distribution challenges.

Manufacturing and Supply Chain Constraints

Raw material sourcing fluctuations.
Stringent quality controls impacting costs.

4. Competitive Landscape and Market Share

Company	Product Portfolio	Market Share (Estimate)	Key Strategies
Sanofi (Betaderm)	Betaderm (topical corticosteroid)	~25%	Brand loyalty, expanding formulations
Mylan (Generic)	Multiple corticosteroids	~20%	Price competition
Teva	Betamethasone formulations	~15%	Global distribution focus
Sandoz	Generics and biosimilars	~10%	Cost leadership, regional expansion
Others	Various regional players	~30%	Niche markets, localized formulations

Market Share Dynamics

Majority driven by generics in mature markets.
Branded products maintain premium positioning via clinical assurances.

5. Regulatory Policies Influencing Market Trajectory

FDA and EMA Stances

Emphasis on safety, prompting label updates and usage guidelines.
Mandatory post-market surveillance for adverse events.

Intellectual Property Trends

Patent expirations typically occur 10-15 years after filing.
Patent litigations and challenges influence market entry timelines.

Reimbursement and Access Policies

Reimbursement varies globally.
Price controls and formulary restrictions impact sales, especially in public healthcare systems.

6. Financial Trajectory and Forecasts

Historical Sales Data (2017–2022)

Year	Global Sales (USD millions)	CAGR	Key Factors
2017	2,400	-	Strong prescription base, limited generics
2018	2,600	8.3%	New formulation approvals, increased prevalence
2019	2,700	3.8%	Regulatory stability
2020	2,850	5.6%	COVID-19 impact on dermatology treatments
2021	2,750	-3.5%	Market saturation, supply chain issues
2022	2,800	1.8%	Recovery, generic penetration

Forecasted Growth (2023–2028)

Year	Estimated Global Sales (USD millions)	CAGR	Assumptions
2023	3,000	7.1%	Increased demand in Asia-Pacific, new formulation launches
2024	3,220	7.3%	Expanded indications, favorable regulatory environment
2025	3,470	7.7%	Evolution of biosimilars, market entry strategies
2026	3,740	8.0%	Greater access in emerging markets
2027	4,040	8.0%	Sustained growth driven by dermatological disorders
2028	4,360	8.0%	Market maturation, ongoing innovation

Drivers of Growth

Demographic Shifts: Aging population increases dermatological needs.
Market Penetration: Expansion into Asia-Pacific and Latin America.
Product Innovation: New formulations, combination therapies.
Regulatory Favorability: Streamlined approval pathways for new uses.

7. Comparative Market Analysis

Compound	Market Size (2022, USD millions)	Main Use	Patent Status	Key Competitors
Betamethasone Dipropionate	2,800	Topical dermatology	Patent expired (major markets)	Sandoz, Teva, Mylan, Sanofi
Clobetasol Propionate	2,200	Ultra-potent corticosteroid	Patent expiration underway	Similar generics, brand players
Hydrocortisone	1,500	Mild dermatitis	Patent status varies	Multiple generic manufacturers
Desonide	800	Mild to moderate eczema	Patent expiration near	Market competition high

8. Strategic Opportunities and Risks

Opportunities

Expansion into developing markets.
Combining betamethasone dipropionate with newer drugs.
Developing long-acting formulations reducing dosing frequency.
Investing in biosimilar development for sustainable growth.

Risks

Regulatory restrictions due to safety concerns.
Price competition from generics.
Market saturation in mature regions.
Supply chain disruptions impacting manufacturing.

Conclusion and Key Takeaways

Market Growth is Robust: Spurred by rising dermatological disorders, especially in aging populations and emerging markets.
Generics Dominate: Patent expirations fuel price erosion, but brand loyalty sustains certain premium segments.
Regulatory Environment is Pivotal: Safety warnings and policy shifts influence prescribing patterns.
Innovation Drives Future Growth: Formulation advances, combination products, and biosimilars will shape the competitive landscape.
Financial Outlook is Positive: CAGR projections of approximately 7-8% through 2028 highlight sustained demand.

Stakeholders should focus on regional expansion, product innovation, and navigating regulatory landscapes to capitalize on the lucrative dermatology corticosteroid market.

FAQs

Q1: What factors most significantly influence the market share of betamethasone dipropionate?
A1: Prevalence of dermatological conditions, patent expiry timings, product efficacy, safety profiles, and regulatory approvals primarily determine market share.

Q2: How does the regulatory environment impact the financial trajectory?
A2: Regulatory restrictions or sanctions can slow sales, while streamlined approval processes and positive safety assessments promote growth.

Q3: What are the primary regions for future market expansion?
A3: Asia-Pacific and Latin America show high growth potential due to increasing dermatological treatment adoption and expanding healthcare infrastructure.

Q4: How will generic competition influence pricing strategies?
A4: Increased generic presence leads to price reductions of 5-10% annually, pressuring profit margins but expanding access.

Q5: Which innovations are expected to drive future demand?
A5: Long-acting formulations, combination therapies, and biosimilars are expected to stimulate sales and address unmet clinical needs.

References

Global Dermatology Market Report (2022). MarketsandMarkets.
FDA Drug Approvals Database (2022). U.S. Food and Drug Administration.
World Health Organization Dermatology Data (2021). WHO Publications.
Patent Status and Market Data (2022). Pharma Intelligence.
Regulatory Updates for Topical Corticosteroids (2021). EMA Publications.

This analysis provides stakeholders with comprehensive insights into the current landscape and future outlook of betamethasone dipropionate, supporting strategic decision-making.

International Patents:	7
US Patents:	18
Tradenames:	13
Applicants:	32
NDAs:	78
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	26
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	73
Patent Applications:	7,670
Drug Prices:	Drug price trends for BETAMETHASONE DIPROPIONATE
Drug Sales Revenues:	Drug sales revenues for BETAMETHASONE DIPROPIONATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BETAMETHASONE DIPROPIONATE
What excipients (inactive ingredients) are in BETAMETHASONE DIPROPIONATE?	BETAMETHASONE DIPROPIONATE excipients list
DailyMed Link:	BETAMETHASONE DIPROPIONATE at DailyMed

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Summary for BETAMETHASONE DIPROPIONATE

Recent Clinical Trials for BETAMETHASONE DIPROPIONATE

Pharmacology for BETAMETHASONE DIPROPIONATE

Anatomical Therapeutic Chemical (ATC) Classes for BETAMETHASONE DIPROPIONATE

Paragraph IV (Patent) Challenges for BETAMETHASONE DIPROPIONATE